Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma-Reference-Cited by-同舟云学术

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma

Published:2020-01-14 Issue:1 Volume:4 Page:203-206
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Illidge Tim M.¹²,Phillips Elizabeth H.³^ORCID,Counsell Nicholas³,Pettengell Ruth⁴,Johnson Peter W. M.⁵^ORCID,Culligan Dominic J.⁶,Popova Bilyana³,Clifton-Hadley Laura³,McMillan Andrew⁷,Hoskin Peter¹²⁸^ORCID,Barrington Sally F.⁹^ORCID,Radford John¹²^ORCID

Affiliation:

1. Division of Cancer Sciences, University of Manchester, National Institutes of Health Research Biomedical Research Centre Manchester Cancer Research Centre, Manchester, United Kingdom;

2. Christie NHS Foundation Trust, Manchester, United Kingdom;

3. Cancer Research UK and UCL Cancer Trials Centre, University College London, London, United Kingdom;

4. Haemato-oncology, St George's, University of London, London, United Kingdom;

5. Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom;

6. Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom;

7. Haematology, Nottingham City Hospitals NHS Trust, Nottingham, United Kingdom;

8. Clinical Oncology, Mount Vernon Hospital, Middlesex, United Kingdom; and

9. King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, Kings College London, King's Health Partners, London, United Kingdom

Abstract

Key Points Baseline maximum tumor diameter is an important predictor of relapse for patients with ES-HL achieving complete metabolic remission. Patients with baseline tumor size ≥5 cm have worse outcomes with ABVD alone and are likely to benefit from consolidation radiotherapy.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/1/203/1552625/advancesadv2019001023.pdf

Reference11 articles.

1. Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID Study;Barrington;J Clin Oncol,2019

2. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial;Cottereau;Blood,2018

3. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma;Radford;N Engl J Med,2015

4. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial;André;J Clin Oncol,2017

5. PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin Study Group;Fuchs;Blood,2018

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward a paradigm shift in prognostication and treatment of early‐stage Hodgkin lymphoma;British Journal of Haematology;2024-07-22

2. Advances in the Management of Classical Hodgkin Lymphoma;Journal of the National Comprehensive Cancer Network;2023-11-25

3. Hodgkin lenfoma hastalarında maksimum tümör çapı ve 18F-FDG PET/BT görüntüleme durumunun genel sağkalıma etkisi;Journal of Medicine and Palliative Care;2023-10-27

4. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime;Nature Reviews Clinical Oncology;2023-07-17

5. [18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription;Seminars in Radiation Oncology;2023-07